{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:08:30Z","timestamp":1791875310978,"version":"4.3.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>Purpose:<\/jats:title><jats:p>To evaluate the safety and effects of oral eplerenone in chronic central serous chorioretinopathy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Prospective, randomized, double-blind, placebo-control study at a tertiary referral academic private practice. For a diagnosis of chronic central serous chorioretinopathy, patients must have had at least 3 months clinical follow-up demonstrating persistent symptoms, subfoveal fluid on spectral-domain optical coherence tomography, and &lt;50% reduction in fluid thickness. Patients were randomized 2:1 (treatment:placebo) to receive eplerenone (25 mg daily for 1 week, then up to 50 mg daily for 8 weeks) or placebo once daily.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Fifteen patients completed the study. Ten patients (15 eyes) were randomized into the eplerenone treatment arm, while the remaining 5 patients (6 eyes) received placebo. After 9 weeks of eplerenone therapy, mean logarithm of the minimal angle of resolution visual acuity improved from 0.394 (Snellen equivalent: 20\/50) to 0.330 (20\/43,<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.04). In the placebo group, the mean logarithm of the minimal angle of resolution visual acuity slightly decreased from 0.313 (20\/41) to 0.342 (20\/44) during the same period (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.21). With respect to anatomic changes, mean maximal subretinal fluid height in the eplerenone group improved from 139.3<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m at baseline to 51.8<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.02), mean subfoveal fluid height improved from 121.4<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m to 29.4<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.01), and mean central subfield thickness improved from 366.2<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m to 283.7<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.02). In comparison with the placebo group, mean maximal subretinal fluid height worsened from 135.9<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m to 172.3<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.32), mean subfoveal fluid height worsened from 92.1<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m to 134.0<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.54), and mean central subfield thickness worsened from 345.0<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m to 380.0<jats:italic toggle=\"yes\">\u03bc<\/jats:italic>m (<jats:italic toggle=\"yes\">P<\/jats:italic>= 0.37). No patients in either group experienced serious adverse events to result in treatment discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>These findings suggest that oral eplerenone therapy is safe and potentially effective in the treatment of chronic central serous chorioretinopathy with persistent subretinal fluid.<\/jats:p><\/jats:sec>","DOI":"10.1097\/iae.0000000000001649","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T14:17:17Z","timestamp":1492697837000},"page":"962-969","source":"Crossref","is-referenced-by-count":81,"title":["A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR)"],"prefix":"10.1097","volume":"38","author":[{"given":"Ehsan","family":"Rahimy","sequence":"first","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"},{"name":"Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Pitcher","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"},{"name":"Eye Associates of New Mexico, Albuquerque, New Mexico."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza K.","family":"Adam","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abtin","family":"Shahlaee","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim A.","family":"Samara","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Vander","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Chiang","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Spirn","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Fineman","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/eye.2010.130","article-title":"Central serous chorioretinopathy: an update on pathogenesis and treatment","volume":"24","author":"Gemenetzi","year":"2010","journal-title":"Eye (Lond)"},{"key":"R3-20230816","first-page":"1","article-title":"Pathogenesis of disciform detachment of the neuroepithelium","volume":"63","author":"Gass","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/ICU.0b013e3283459826","article-title":"Review and update of central serous chorioretinopathy","volume":"22","author":"Ross","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0039-6257(02)00338-7","article-title":"Central serous chorioretinopathy and glucocorticoids","volume":"47","author":"Bouzas","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/S0161-6420(02)01117-X","article-title":"Corticosteroids and central serous chorioretinopathy","volume":"109","author":"Carvalho-Recchia","year":"2002","journal-title":"Ophthalmology"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IAE.0b013e31815ec2c8","article-title":"Central serous chorioretinopathy associated with sildenafil","volume":"28","author":"Fraunfelder","year":"2008","journal-title":"Retina"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/IAE.0000000000000198","article-title":"Central serous chorioretinopathy in patients receiving exogenous testosterone therapy","volume":"34","author":"Nudleman","year":"2014","journal-title":"Retina"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00417-008-0837-0","article-title":"Obstructive sleep apnea in patients with central serous chorioretinopathy","volume":"246","author":"Kloos","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajo.2016.02.012","article-title":"Shift work: a risk factor for central serous chorioretinopathy","volume":"165","author":"Bousquet","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/ICB.0b013e3181f66ac0","article-title":"Central serous chorioretinopathy associated with narcolepsy","volume":"5","author":"Kim","year":"2011","journal-title":"Retin Cases Brief Rep"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/bjo.68.11.815","article-title":"Long-term follow-up of central serous chorioretinopathy","volume":"68","author":"Gilbert","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1034\/j.1600-0420.2001.079004417.x","article-title":"Long-term follow-up of idiopathic central serous chorioretinopathy without laser","volume":"79","author":"Bujarborua","year":"2001","journal-title":"Acta Ophthalmologica Scand"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0002-9394(99)00075-6","article-title":"Systemic findings associated with central serous chorioretinopathy","volume":"128","author":"Tittl","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ophtha.2003.09.024","article-title":"Risk factors for central serous chorioretinopathy: a case-control study","volume":"111","author":"Haimovici","year":"2004","journal-title":"Ophthalmology"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/IAE.0b013e318050ca69","article-title":"Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy","volume":"27","author":"Meyerle","year":"2007","journal-title":"Retina"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1755-3768.2008.01467.x","article-title":"Ketoconazole in the treatment of central serous chorioretinopathy: a pilot study","volume":"88","author":"Golshahi","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1097\/IAE.0b013e31821c3ef6","article-title":"Oral mifepristone for chronic central serous chorioretinopathy","volume":"31","author":"Nielsen","year":"2011","journal-title":"Retina"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/IAE.0b013e3181f04a35","article-title":"Finasteride for chronic central serous chorioretinopathy","volume":"31","author":"Forooghian","year":"2011","journal-title":"Retina"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/bjophthalmol-2011-300183","article-title":"Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy","volume":"96","author":"Steinle","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/ICB.0b013e3182235561","article-title":"Chronic central serous chorioretinopathy responsive to rifampin","volume":"6","author":"Ravage","year":"2012","journal-title":"Retin Cases Brief Rep"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/03602537808993782","article-title":"Spironolactone: disposition, metabolism, pharmacodynamics and bioavailability","volume":"8","author":"Karim","year":"1978","journal-title":"Drug Metab Rev"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"De Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI61427","article-title":"Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy","volume":"122","author":"Zhao","year":"2012","journal-title":"J Clin Invest"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/IAE.0000000000000748","article-title":"Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study","volume":"36","author":"Ghadiali","year":"2016","journal-title":"Retina"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00417-014-2780-6","article-title":"Spironolactone in the treatment of central serous chorioretinopathy - a case series","volume":"252","author":"Herold","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","article-title":"Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study","volume":"35","author":"Bousquet","year":"2015","journal-title":"Retina"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000444058","article-title":"Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: a comparative analysis","volume":"56","author":"Kapoor","year":"2016","journal-title":"Ophthalmic Res"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1097\/IAE.0b013e318297a07a","article-title":"Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study","volume":"33","author":"Bousquet","year":"2013","journal-title":"Retina"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"e488","DOI":"10.1111\/aos.12392","article-title":"The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy","volume":"92","author":"Breukink","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"R33-20230816","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3928\/23258160-20150422-06","article-title":"Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series","volume":"46","author":"Salz","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R34-20230816","first-page":"310","article-title":"Oral eplerenone for the management of chronic central serous chorioretinopathy","volume":"8","author":"Singh","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5301\/ejo.5000727","article-title":"Eplerenone in patients with chronic recurring central serous chorioretinopathy","volume":"26","author":"Leisser","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s00417-016-3373-3","article-title":"Clinical experience with eplerenone to treat chronic central serous chorioretinopathy","volume":"254","author":"Cakir","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/OPTH.S86778","article-title":"Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy","volume":"9","author":"Chin","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.5.2.2","article-title":"Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy","volume":"5","author":"Daruich","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jfo.2016.01.008","article-title":"Eplerenone treatment in chronic central serous chorioretinopathy [in French]","volume":"39","author":"Sampo","year":"2016","journal-title":"J Fr Ophtalmol"},{"key":"R40-20230816","first-page":"1369","article-title":"Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report","volume":"17","author":"Gruszka","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R41-20230816","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/ICB.0000000000000147","article-title":"Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case","volume":"9","author":"Ryan","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"R43-20230816","first-page":"1186","article-title":"Statistical analysis of multi-eye data in ophthalmic research","volume":"26","author":"Ray","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R44-20230816","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am J Physiol Ren Physiol"},{"key":"R45-20230816","doi-asserted-by":"crossref","first-page":"e012","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"R46-20230816","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1242\/dev.109835","article-title":"Glucocorticoid receptors in the retina, Muller glia and the formation of Muller glia-derived progenitors","volume":"141","author":"Gallina","year":"2014","journal-title":"Development"},{"key":"R47-20230816","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1096\/fj.09-154344","article-title":"The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Mu\u0308ller glial cells","volume":"24","author":"Zhao","year":"2010","journal-title":"FASEB J"},{"key":"R48-20230816","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"R49-20230816","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2146\/ajhp050041","article-title":"Aldosterone antagonists in the treatment of heart failure","volume":"63","author":"Marcy","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"R50-20230816","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R51-20230816","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201805000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:25:00Z","timestamp":1750202700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201805000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001649","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}